Biocompatible nanomagnetic discs and methods of use thereof
AssigneeAccudx Corporation
InventorsRaveendran POTTATHIL, Sanjay DESHMUKH, Kiran KHARAT
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions including biocompatible magnetizeable nanoparticles. The nanoparticles have a diameter (average diameter) from about 10 to about 300 nanometers and are biocompatible and magnetic. The nanoparticles may be a disc formed from iron oxide. The disc may be comjugated to a target-binding moiety capable of binding a target. The target may be cancer cells, pathogens, fat cells, or atherosclerotic plaques.
Claims91
A composition comprising a magnetizeable nanoparticle, wherein the nanoparticle is disc shaped, has a diameter of about 10 to about 300 nanometers, comprises iron oxide, and is conjugated to a target-binding moiety capable of binding a target.
A method of treating a subject with a disease condition, the method comprising:
- (i) administering to the subject an effective amount of a composition comprising a magnetizeable nanoparticle, wherein the nanoparticle has a diameter of about 10 to about 300 nanometers, comprises iron oxide and a biocompatible agent, and is conjugated to a target-binding moiety capable of binding a target;
- and
- (ii) exposing the subject to an energy source for a time period sufficient to allow the nanoparticle to move in a manner that causes disruption, apoptosis, and/or ablation of the target.
A device comprising:
- a filtration chamber configured to receive blood or plasma comprising target cells;
- and
- a matrix disposed within said filtration chamber and wherein the matrix comprises a magnetizeable nanoparticle;
- wherein the magnetizeable nanoparticle has a diameter of about 10 to about 300 nanometers, comprises iron oxide, and is conjugated to a target-binding moiety capable of binding said target cells;
- and
- wherein the device is configured to apply energy sufficient to allow the nanoparticle to move in a manner that causes disruption, apoptosis, and/or ablation of the target.
A method of treating a subject with a blood cancer, the method comprising:
- (i) administering ex vivo hemofiltration to said subject wherein blood is removed from the subject and filtered through a device comprising (1) a filtration chamber configured to receive blood or plasma comprising target cells, and (2) a matrix comprising magnetizeable nanoparticles disposed within said filtration chamber, wherein the nanoparticles are conjugated to a target-binding moiety;
- (ii) incubating the blood or plasma with the matrix for a sufficient time to allow binding of the nanoparticles to the target cells;
- (iii) exposing the device with the blood to an energy source for a time period sufficient to allow the magnetizeable nanoparticles to move in a manner that causes disruption, apoptosis, and/or ablation of the target cells;
- and
- (ii) returning blood to said subject, wherein the blood is at least 80% free of target cells.
A method of treating a disease lesion in a subject having a lesion associated with a disease or condition, comprising:
- a) intravenously administering to the subject a composition comprising a nanoparticle conjugated to a biocompatible agent and a target-binding moiety capable of binding the lesion;
- and b) after administering the composition, exposing the lesion to an energy source sufficient to cause the nanoparticles to move in a manner that causes disruption, apoptosis, and/or ablation of the lesion.
A method of manufacturing a biocompatible magnetizeable nanoparticle, the method comprising:
- (i) combining iron oxide powder with water, a biocompatible agent, and a buffer until an immiscible solution of Fe2O3 is formed;
- (ii) adjusting the pH to about 10;
- (iii) adding a target-binding moiety under conditions sufficient for the target-binding moiety to conjugate to the nanoparticle and form a solution;
- and
- (iv) spray-drying the solution to form nanoparticles with a diameter of about 10 to about 300 nanometers.
Dependencies are inferred from the claim text.